Showing results (211-220 of 238) with videos related to

Sort By:
Pageof 24
Frontiers in Immunology|August 8, 2022
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 StudyBeatriz Perdiguero, Benedikt Asbach, Carmen E Gómez, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging studyPaul A Goepfert, Bo Fu, Anne-Laure Chabanon, et al.
Current Oncology (Toronto, Ont.)|September 22, 2022
Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational StudyAristotelis Bamias, Kimon Tzannis, Roubini Zakopoulou, et al.
Leukemia & Lymphoma|January 28, 2012
Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphomaMaria Dimou, Maria K Angelopoulou, Gerassimos A Pangalis, et al.
The Lancet. Infectious Diseases|March 23, 2020
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trialMilagritos D Tapia, Samba O Sow, Birahim P Ndiaye, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 25, 2024
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine TrialNigel Garrett, One Dintwe, Cynthia L Monaco, et al.
JCI Insight|January 25, 2024
Lipodystrophy in methylmalonic acidemia associated with elevated FGF21 and abnormal methylmalonylationIrini Manoli, Justin R Sysol, PamelaSara E Head, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 10, 2025
Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trialJoon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.
PLOS Global Public Health|September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trialVimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.
Pageof 24